DURHAM, N.C., Oct. 7, 2002 /PRNewswire-FirstCall/ --
Triangle Pharmaceuticals, Inc. (Nasdaq: VIRS) announced today that Daniel
Welch, Chairman and Chief Executive Officer, will present at the UBS Warburg
2002 Global Life Sciences Conference. Triangle's presentation is scheduled
for 3:30 p.m. ET on Thursday, October 10, 2002 at The Plaza in New York City.
The presentation will be Webcast through the UBS Warburg website at
http://www.ubswarburg.com and will be archived for replay for one month after the
presentation. Slides used in the presentation will be available and archived
on the Triangle Pharmaceuticals website at http://www.tripharm.com.
Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company
engaged in the development of new antiviral drug candidates, with a particular
focus on therapies for the human immunodeficiency virus (HIV) and the
hepatitis B virus. Triangle's proprietary drug candidates under development
for HIV and/or hepatitis B include Coviracil(R) (emtricitabine), amdoxovir
(formerly DAPD), and clevudine (formerly L-FMAU). Triangle is also developing
immunotherapies for hepatitis B in collaboration with Dynavax Technologies
Corporation (Dynavax) utilizing Dynavax' immunostimulatory sequence (ISS)
technology. More information about Triangle's portfolio, management and
product development strategy is available on Triangle's website.
SOURCE Triangle Pharmaceuticals, Inc.
 back to top
Related links:
http://www.tripharm.com
CONTACT:
Daniel G. Welch, Chairman and Chief Executive
Officer, or Robert F. Amundsen, Jr., Executive Vice President and
Chief Financial Officer, both of Triangle Pharmaceuticals, Inc.,
+1-919-493-5980
|
